Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus VELPHORO.
AURYXIA vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category C
Category C
Phosphate Binder
Phosphate Binder